when are these morons going to learn that sending messy html formatted spam
isn't going to make them any friends on an open source program's mailing list?
sheesh...
On Wed, 3 Jan 2001 16:55:16, <[EMAIL PROTECTED]> said:
> <html>
>
> <head>
> <meta http-equiv="Content-Type" content="text/html; charset=windows-1252">
> <meta name="GENERATOR" content="Microsoft FrontPage 4.0">
> <meta name="ProgId" content="FrontPage.Editor.Document">
> <title></title>
> </head>
>
> <body bgcolor="#CCCCCC">
>
> <div align="center">
>
> <table border="2" width="550" cellpadding="14" cellspacing="5"
>bordercolor="#003366" bordercolorlight="#003366" bordercolordark="#003366">
> <tr>
> <td width="100%" bgcolor="#FFFFFF">
>
> <p class="MsoBodyText" align="left"><font face="Arial" size="2"><img border="0"
>src="http://www.emedsecurities.com/sitetools/images/emed_logobanner_small.jpg"
>align="right" width="138" height="31"></font></p>
>
> <p class="MsoBodyText2"> </p>
>
> <p class="MsoBodyText2" align="center"><b><font color="#003399" face="Verdana"
>size="4">Be one of the 50 investors selected to Beta Test our online trading site and
>be eligible to purchase shares of future IPOs we participate in!</font><font
>color="#003399" face="Verdana" size="2">**</font></b></p>
>
> <p class="MsoBodyText2" align="left" style="text-align:left"><font size="2"
>face="Arial">As a potential investor in the Life Sciences, you should be well aware
>of the rapid developments taking place in both the pharmaceutical and biotech
>industries. In fact, the entire product pipeline is teeming with over
> 2,000 drugs under development and an additional 300 in Phase III or awaiting FDA
>approval.</font></p>
>
> <p class="MsoBodyText2" align="left" style="text-align:left"><font size="2"
>face="Arial">How do <u>you</u> make the most of your knowledge to make informed
>investment choices? How can <u>you</u> capitalize on the tremendous financial
>opportunities that are available right now? The answer is eMedsecurities. We
> are an electronic investment bank and online trading site that facilitates a
>knowledge-based approach toward investing in the Life Sciences Market.</font></p>
>
> <p class="MsoBodyText2" align="center"><b><font face="Verdana" color="#003399"
>size="4">Help Test Our Revolutionary New Investment Web Site and Discover a Wealth of
>Opportunities in the Small Cap Life Sciences Market!</font></b></p>
>
> <p class="MsoBodyText2" align="left" style="text-align:left"><font size="2"
>face="Arial">To see if you qualify to test the launch of our new online trading site
>(Beta version) and to get in on this exciting opportunity, please <a
>href="http://www.emedsecurities.com/redir.asp?name=0103010100A00031A3">click
> here</a>:<span style="mso-bidi-font-size: 12.0pt">**</span> As a participating Beta
>Tester, you will receive:</font><span style="mso-bidi-font-size: 12.0pt; font-weight:
>normal"><font size="2" face="Arial"><o:p>
> </o:p>
> </font></span></p>
>
> <ul>
> <li>
>
> <p class="MsoNormal" style="mso-list: l1 level1 lfo6; tab-stops: list
>.5in"><b><u><font size="2" face="Arial">Eligibility</font></u><font size="2"
>face="Arial"> </font></b><font size="2" face="Arial">to purchase shares in IPOs that
>eMedsecurities participates in for as long as you maintain your
>account**</font><b><u><font
> size="2" face="Arial"><br>
> </font></u></b></li>
> <li>
>
> <p class="MsoNormal" style="mso-list: l1 level1 lfo6; tab-stops: list
>.5in"><b><u><font size="2" face="Arial">Valuable</font></u><font size="2"
>face="Arial"> </font></b><font size="2" face="Arial">research of the entire Product
>Pipeline of companies, including stages of clinical development, by industry or
> specific disease</font><b><u><font size="2" face="Arial"><br>
> </font></u></b></li>
> <li>
>
> <p class="MsoNormal" style="mso-list: l1 level1 lfo6; tab-stops: list
>.5in"><b><u><font size="2" face="Arial">Useful</font></u><font size="2" face="Arial">
></font></b><font size="2" face="Arial">information about industry trends, recent
>developments and upcoming IPOs</font><b><u><font size="2" face="Arial"><br>
> </font></u></b></li>
> <li>
>
> <p class="MsoNormal" style="mso-list: l1 level1 lfo6; tab-stops: list
>.5in"><b><u><font size="2" face="Arial">Commitment</font></u><font size="2"
>face="Arial"> </font></b><font size="2" face="Arial">to customer service featuring
>our Live Customer Service Online</font><b><u><font size="2" face="Arial"><br>
> </font></u></b></li>
> <li>
>
> <p class="MsoNormal" style="mso-list: l1 level1 lfo6; tab-stops: list
>.5in"><b><u><font size="2" face="Arial">Dedication</font></u><font size="2"
>face="Arial"> </b>to fast trade executions at the best possible price <b><o:p>
> </b></font></li>
> </ul>
>
> <p class="MsoBodyText"><font size="2" face="Arial">Our knowledge-based approach
>incorporates the following:</font></p>
>
> <ul style="margin-top:0in" type="disc">
> <li class="MsoNormal" style="mso-list:l5 level1 lfo4;tab-stops:list 5in"><b><font
>size="2" face="Arial">Comprehensive Disease Hub Database</font></b><font size="2"
>face="Arial">- Our Disease Hub Database effectively consolidates scientific and
>financial information into one easy-to-understand abstract. It is
> an invaluable resource for investing in the Life Sciences Market.<br>
> </font></li>
> <li class="MsoNormal" style="mso-list:l5 level1 lfo4;tab-stops:list 5in"><b><font
>size="2" face="Arial">Advisory Boards</font></b><font size="2" face="Arial">- To help
>keep us aware of trends, our members include Nobel Laureates in physiology and
>medicine, pioneers in drug discovery, as well as recognized
> top strategic planners in the worldwide Pharmaceutical Industry.<br>
> </font></li>
> <li class="MsoNormal" style="mso-list:l5 level1 lfo4;tab-stops:list 5in"><b><font
>size="2" face="Arial">Webcasts</font></b><font size="2" face="Arial">- Participate in
>regular webcasts and live chat sessions with leaders in the Pharmaceutical and
>Biotechnology spaces.</font></li>
> </ul>
> <ul style="margin-top:0in" type="disc">
> <li class="MsoNormal" style="mso-list:l5 level1 lfo4;tab-stops:list
>5in"><b><u><font size="2" face="Arial">Free</font></u><font size="2" face="Arial">
>eMedUpdates - </font></b><font size="2" face="Arial">Get periodic updates delivered
>directly to your email on upcoming IPOs we participate in, webcasts and
> new features. [<a
>href="http://www.emedsecurities.com/sitetools/qualified/emedupdate.asp">Sign
>Up</a>]</font></li>
> </ul>
>
> <p class="MsoBodyText3"><font size="2" face="Arial">Now you can take advantage of
>the wealth of information we have compiled to make more informed investment decisions
>in the Life Sciences. eMedsecurities enables you to learn about new research and
>upcoming treatments for diseases like arthritis, breast and
> colon cancer, Parkinson�s disease and more. Then examine the financial information
>about the companies that are developing them, all from a single source.</font></p>
>
> <p align="center"><b><font face="Arial" color="#003399" size="3">Buy and sell any
>publicly traded company with eMedsecurities!</font></b>
>
> <p class="MsoNormal"><font size="2" face="Arial"><a
>href="http://www.emedsecurities.com/redir.asp?name=0103010100A00031A3">Click
>here</a>: to see if you qualify to become a Beta Tester of our new Web site. Your
>participation and feedback will be greatly appreciated while assuring you eligibility
>to purchase
> shares of future IPOs in which we take part!</font></p>
>
> <p class="MsoNormal"><b><font size="2" face="Arial">Please note:</font></b><font
>size="2" face="Arial"> All applications for the Beta Test must be in by 1/12/01 to be
>considered.</font></p>
>
> <p class="MsoNormal"> </p>
>
> <p class="MsoNormal"> </p>
>
> <p class="MsoNormal"> </p>
>
> <p class="MsoNormal"><font face="Arial" size="1">Research indicated that you might
>benefit from our offer. To discontinue receipt of further notice and to be removed
>from our database, simply click here: <a
>href="mailto:[EMAIL PROTECTED]?subject=remove">[EMAIL PROTECTED]?subject=remove</a>,
> or go to
> our <a href="http://www.emedsecurities.com/sitetools/ads/remove.asp">Opt Out
>page</a>, to be instantly and permanently removed. We respect all removal
>requests.</font></p>
>
> <p class="MsoNormal"><font face="Arial" size="1">**<b> Restrictions Apply:</b>
><b><span style="color:red">Beta test open only to those residents of: AK, AR, CA, CT,
>DC, DE, FL, GA, ID, IN, IA, KY, LA, MA, MD, ND, NV, NY, OH, PA, SC, SD, VA, WA, WV,
>WI, WY.</span></b> Initial Public Offerings are considered speculative investments
>and as such may not be appropriate for every investor.
> If an investor chooses to participate in IPOs, there are certain restrictions that
>apply:<b><span style="color:red">Flipping</span> - </b>The first time an investor
>sells his/her shares within the first 30 days the issue is trading in the secondary
>market, that investor will not be allocated shares for the
> next 90 days following the sale. The second time that investor �flips�; they
>will not be allocated IPO shares for 180 days. The third time that investor
>�flips�; they lose their IPO allocations permanently.<span style="color:red">
><b>Transferring shares</b></span><b> - </b>If the investor
> transfers IPO shares out of their account within the first 30 days the issue is
>trading in the secondary market, they will permanently lose their IPO
>allocations. <b>Beta investors will be chosen from all of the applicants based
>on their income, net worth and investing experience.</b> IPO shares
> will only be allocated from transactions in which eMedsecurities is participating
>in the underwriting. 010301-0100-A0003-1-A3</font>
> </td>
> </tr>
> </table>
>
> </div>
>
> </body>
>
> </html>
>
>
--
Forrest English
http://truffula.net
"I don't like this air, but that doesn't
mean I'm going to stop breathing."
-Doug Martsch
